Shengni Hua

1.6k citations
22 papers · 1.1k indexed · 1 hit paper · h-index 16

Shengni Hua

21 papers receiving 1.1k citations

Hit Papers

Hepatocellular carcinoma: signaling pathways, targeted th...552024202620251020304050

Peers

Shengni Hua
Comparison fields: 5 of 86
  • Cancer Research 587
  • Molecular Biology 829
  • Oncology 253
  • Hepatology 30
  • Pulmonary and Respiratory Medicine 122
Replace Shuang Han with:
Shuang Han China
Duc‐Hiep Bach South Korea
Longchang Jiang Germany
Wataru Usuba Japan
Huizhen Zhang China
Peiguo Cao China
Zhangqian Chen China
Shucai Yang China
Ramesh Butti India
Shengni Hua relative to Shuang Han China Shuang Han's profile →
Citations per field
00.5×4.2×
Shuang Han · 1×
Citations per year

Countries citing papers authored by Shengni Hua

Since Specialization
Citations

This map shows the geographic impact of Shengni Hua's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shengni Hua with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shengni Hua more than expected).

Fields of papers citing papers by Shengni Hua

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shengni Hua. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shengni Hua. The network helps show where Shengni Hua may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Shengni Hua, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Shengni Hua Line = papers co-authored together Shengni Hua links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1
Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapybreakdown →
202455
2 202322
3 202011
4 202031
5 20209
6 202028
7 201913
8 201972
9 201897
10 201869
11 201658
12 2015211
13
[Effect of HMGB1 on proliferation of human nasopharyngeal carcinoma cell line C666-1 in vitro].
20153
14 201420
15 201416
16 2014150
17 201441
18 201331
19 2013111
20 201314

About Shengni Hua

Shengni Hua is a scholar working on Cancer Research, Molecular Biology and Geriatrics and Gerontology, having authored 22 papers that have together received 1.1k indexed citations. Recurring topics across this work include RNA modifications and cancer (10 papers), MicroRNA in disease regulation (6 papers), Cancer, Hypoxia, and Metabolism (4 papers), Epigenetics and DNA Methylation (3 papers), Ferroptosis and cancer prognosis (3 papers), Cancer-related gene regulation (3 papers), Ubiquitin and proteasome pathways (2 papers) and Cancer-related Molecular Pathways (2 papers). The work is most often cited by research in Cancer Research (587 citations), Molecular Biology (829 citations) and Oncology (253 citations). Shengni Hua has collaborated with scholars based in China and United States. Frequent co-authors include Weiyi Fang, Dehua Wu, Chengdong Liu, Li Liu, Qiaofen Fu, Meixiao Zhan, Ligong Lu, Yiyu Chen, Yue Fan and Chuanhui Cao. Their work appears in journals such as SHILAP Revista de lepidopterología, PLoS ONE and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026